...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis
【24h】

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis

机译：特立帕肽治疗糖皮质激素引起的骨质疏松症的长期安全性，疗效和患者可接受性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect of glucocorticoid use is increased risk of fracture. Many different therapies are indicated to prevent and treat this condition; many guidelines exist that suggest appropriate use of both glucocorticoids and the medications approved to prevent this common side effect of glucocorticoid therapy. Nevertheless, 30%–50% of patients on long-term glucocorticoid therapy sustain a fracture. Teriparatide, recombinant human parathyroid hormone (1–34), is a daily self-injectable therapy for 24 months approved for use in patients taking long-term glucocorticoids. Teriparatide has been shown to increase bone mineral density and reduce vertebral fracture risk in glucocorticoid-treated patients. Glucocorticoids have many adverse effects on bone that teriparatide has been shown to prevent or negate. Given the fact that preventive therapy for glucocorticoid-induced osteoporosis is often not prescribed, one wonders whether a daily self-injectable therapy for this condition would be prescribed by physicians and accepted by patients. This article reviews the epidemiology, pathophysiology, treatment, guidelines, and persistence data (when available) for patients with glucocorticoid-induced osteoporosis treated with teriparatide.
机译：摘要：糖皮质激素是治疗许多医学专业中多种疾病的常用处方药。使用糖皮质激素的最常见但大部分未发现的副作用之一是骨折风险增加。指出有许多不同的疗法可以预防和治疗这种情况。存在许多指南，建议适当使用糖皮质激素和批准的药物可预防糖皮质激素治疗的这种常见副作用。但是，长期接受糖皮质激素治疗的患者中有30％–50％会骨折。特立帕肽是一种重组人甲状旁腺激素（1-34），是每天24个月的自注射疗法，已被批准用于长期服用糖皮质激素的患者。特立帕肽已显示在糖皮质激素治疗的患者中可增加骨矿物质密度并降低椎骨骨折的风险。糖皮质激素对骨骼有许多不良影响，特立帕肽可以预防或消除这种副作用。鉴于通常没有开出预防糖皮质激素引起的骨质疏松症的处方这一事实，有人想知道对于这种情况，每天是否可以自行注射药物，是否会被医生开处方并为患者所接受。本文回顾了接受特立帕肽治疗的糖皮质激素诱发的骨质疏松症患者的流行病学，病理生理学，治疗，指南和持续性数据（如果可用）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号